Original Research

Models for Implementing Buprenorphine Treatment in the VHA

Although proven as a cost-effective treatment in VHA settings, buprenorphine currently is underutilized by VA practitioners. These authors review the drug’s advantages and describe how some VA programs are employing it successfully


 

Recommended Reading

Nearly one in five develop mental illness following COVID-19
Federal Practitioner
Situation ‘dire’ as COVID spike in West, Midwest worsens, experts say
Federal Practitioner
Major breakthrough? Average 10% weight loss with semaglutide
Federal Practitioner
Don’t miss cardiovascular risk factors in transgender patients
Federal Practitioner
New guidelines address diabetes management in kidney disease
Federal Practitioner
Escalate HIV adherence strategies amid COVID-19
Federal Practitioner
Lancet panel calls for urgent global action to combat diabetes
Federal Practitioner
Intravenous iron reduces HF readmissions: AFFIRM-AHF
Federal Practitioner
Chronic inflammatory diseases vary widely in CHD risk 
Federal Practitioner
Pembrolizumab approved for triple-negative breast cancer
Federal Practitioner